Skip to main content

Table 4 Multivariate analysis of MYC and BCL2 coexpression and prognostic scoring systems for progression-free survival in patients with PCNS-DLBCL treated with combined MVP and radiotherapy

From: MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

 

PFS

 

HR

95 % CI

P

Age

0.983

0.922–1.049

0.605

N-B, 2–3

1.146

0.464–2.830

0.768

MSKCC, 2–3

4.975

0.715–34.613

0.105

MYC (≥40) and BCL2 (≥60), dual positive

4.372

1.430–13.367

0.010

  1. Abbreviations: PFS progression-free survival, HR hazard ratio, CI confidence interval, N-B Nottingham- Barcelona, MSKCC Memorial Sloan Kettering Cancer Center